Drug Metabolism and Pharmacokinetics Research Laboratories, Research and Development Division, Daiichi Sankyo Co., Ltd, 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.
Arch Toxicol. 2011 Apr;85(4):347-53. doi: 10.1007/s00204-010-0594-9. Epub 2010 Sep 25.
We investigated hepatotoxicity induced by ticlopidine (TIC) in glutathione (GSH)-depleted rats by pre-treatment of a well-known GSH synthesis inhibitor, L-buthionine-S,R-sulfoxinine (BSO). Although sole administration of either TIC or BSO showed no signs of hepatotoxicity, combined administration of TIC with BSO induced hepatotoxicity, which was characterized by centrilobular necrosis of the hepatocytes and an elevation of plasma alanine aminotransferase activity. Administration of radio-labeled TIC in combination with BSO resulted in significantly higher covalent binding to rat liver proteins than that observed after sole dosing of radio-labeled TIC. Pre-treatment of 1-aminobenzotriazole, a non-specific inhibitor of P450s, completely suppressed both hepatotoxicity and the increased hepatic covalent binding caused by TIC co-treatment with BSO. The results obtained in this animal model suggest that GSH depletion and covalent binding may be involved in hepatotoxicity induced by TIC. These observations may help to understand the risk factors and the mechanism of hepatotoxicity of TIC in humans.
我们通过预先用一种众所周知的谷胱甘肽合成抑制剂 L-丁硫氨酸-S,R-亚砜(BSO)处理谷胱甘肽(GSH)耗竭的大鼠来研究噻氯匹定(TIC)引起的肝毒性。尽管单独使用 TIC 或 BSO 均未显示出肝毒性的迹象,但 TIC 与 BSO 的联合给药会引起肝毒性,其特征为肝细胞的中央小叶坏死和血浆丙氨酸氨基转移酶活性升高。与单独给予放射性标记的 TIC 相比,给予放射性标记的 TIC 与 BSO 联合给药会导致大鼠肝蛋白的共价结合显著增加。1-氨基苯并三唑,一种非特异性 P450s 抑制剂的预处理完全抑制了 TIC 与 BSO 共同处理引起的肝毒性和肝内共价结合的增加。在该动物模型中获得的结果表明,GSH 耗竭和共价结合可能参与了 TIC 引起的肝毒性。这些观察结果可能有助于理解 TIC 在人类中的肝毒性的危险因素和机制。